Plain-English translation of NCT06168461 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Women who have had preeclampsia during pregnancy face a higher risk of heart disease later in life, even if they were otherwise healthy. This study is testing whether , a common over-the-counter medication, can help repair and protect blood vessels after preeclampsia. Researchers want to see if this treatment might prevent heart problems down the road.
Right now, doctors don't have a specific treatment to help women recover from the blood vessel damage that preeclampsia can cause. This study exists to find out whether this medication could be a simple, safe way to reduce the risk of heart disease in women who've had preeclampsia.
You likely qualify if…
You likely don't qualify if…
You will take either or a placebo (a dummy pill) once daily at bedtime for 12 weeks. The study will measure how well your blood vessels are working before, during, and after the treatment period to see if the medication helps. You'll likely have a few visits for blood vessel testing and health assessments.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States
Sponsor
Anna Stanhewicz, PhD
Enrollment target
~40 participants
Started
November 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 50 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anna Reid-Stanhewicz, PHD
Anna Stanhewicz, PhD
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.